Insufficient Showing of Public Availability of Prior Art and Strong, Unrebutted Evidence of Commercial Success Defeats IPR Petition

Mar 31, 2017

Reading Time : 2 min

The ’135 Patent, which is owned by the Trustees of the University of Pennsylvania (“UPenn”), is directed to a method of treating a patient suffering from hyperlipidemia and/or hypercholesterolemia by administering compounds that inhibit microsomal triglyceride transport protein (MTP) according to a dosage regimen that minimizes serious side effects.  The ’135 Patent teaches that, although several MTP inhibitors were developed by pharmaceutical companies, clinical development of these drugs was discontinued due to significant and serious hepatotoxic side effects observed during clinical trials.  The inventors of the patent discovered that these serious side effects can be significantly reduced by utilizing a dosage regimen that starts with a low dose of the MTP inhibitor, lomitapide, followed by a gradual step-wise increase in dose levels. The PTAB instituted a trial based on the Coalition’s arguments that the challenged claims are obvious in view of two combinations of prior art references: (1) the Stein presentation and the Chang reference, and (2) the Pink Sheet and the Chang reference.

First, the PTAB found that the Coalition failed to establish that the challenged claims were unpatentable based on the Stein presentation and the Chang reference because the Coalition did not demonstrate that Stein’s presentation constituted a printed publication for prior art purposes. The Coalition did not establish that the Stein presentation, which was presented as a webcast at Analyst Day at PPD, Inc., was publicly available because there is no evidence that: (1) a skilled artisan would have accessed the presentation via webcast or on the PPD website, and (2) the presentation was posted online prior to the priority date of the ’135 Patent.

Second, the PTAB found that the Coalition did not prove by a preponderance of the evidence that the challenged claims were obvious in view of the Pink Sheet and the Chang reference because the Coalition did not establish a reasonable expectation of success. Although the Pink Sheet teaches the claimed dosing schedule with an MTP inhibitor (implitapide), the Coalition did not establish that a skilled artisan would have reasonably expected or predicted that lomitapide as taught by the Chang reference could be substituted for implitapide with a reasonable expectation of effectively treating hyperlipidemia or hypercholesterolemia without unacceptable levels of toxicity.    

Finally, the PTAB found that the evidence of secondary considerations in this case supported a finding ofnonobviousness.UPenn established that its licensee,Aegerion, received Food & Drug Administration approval forJUXTAPID®, alomitapide treatment for homozygous familial hypercholesterolemia, which has generated more than $420 million in revenue since its launch in 2013. The Coalition did not challenge the commercial success of the patent, but instead argued thatUPenn did not establish a nexus betweenJUXTAPID®and its commercial success and that the commercial success is not commensurate with the scope of the claims. The PTAB stated that nexus is presumed becauseJUXTAPID®is the commercial embodiment of the challenged claims, and, in addition,UPenn presented evidence that theJUXTAPID®marketing prominently displays the dosing schedule encompassed by the claims. The PTAB found that the challenged claims are commensurate in scope with the patent owner’s evidence of commercial success because, contrary to the Coalition’s arguments, theJUXTAPID®website describes the claimed dosing method. Thus, the PTAB found that the unrebutted evidence of commercial success supports the patentability of the challenged claims.

The Trustees of the University of Pennsylvania v. Coalition for Affordable Drugs VIII, LLC, IPR2015-01835, Paper No. 56 (PTAB Mar. 6, 2017).

Share This Insight

Previous Entries

IP Newsflash

August 11, 2025

In considering a motion to dismiss infringement claims for two related patents, the District of Massachusetts recently held that pre-suit knowledge of a “parent” patent, without more, is insufficient to establish pre-suit knowledge of the “child” patent for purposes of indirect and willful infringement.

...

Read More

IP Newsflash

August 8, 2025

Following a jury verdict finding trade secret misappropriation, the District Court for the District of Massachusetts granted-in-part a plaintiff’s motion for a permanent injunction to prohibit defendants from using plaintiff’s trade secrets. The district court further required defendants to reassign to plaintiff patents and patent applications that disclosed or were derived from plaintiff’s trade secrets as part of its equitable relief.

...

Read More

IP Newsflash

August 6, 2025

In ruling on a recent motion to strike, a judge in the Eastern District of Texas permitted a damages expert to rely on a damages theory based on defendant’s “avoided costs,” holding that this theory did not run afoul of the “entire market value rule.”

...

Read More

IP Newsflash

August 5, 2025

The Federal Circuit recently vacated a decision by the Patent Trial and Appeal Board after concluding that the board’s analysis of licensing evidence offered as a secondary consideration of nonobviousness constituted legal error and was not supported by substantial evidence. According to the court, the board applied a more exacting and improperly heightened nexus standard than is required by law for license evidence.

...

Read More

IP Newsflash

August 5, 2025

A Northern District of California judge recently granted a motion to reconsider his summary judgment ruling that defendant was barred from raising certain “device art” due to IPR estoppel under 35 U.S.C. § 315(e)(2). In the original ruling, the judge adopted the broader rule that IPR estoppel applies to device art that is “materially identical” to patents or printed publications that petitioners raised, or could have raised, in an IPR. Following that ruling, however, the Federal Circuit issued its Ingenico decision adopting the narrower view that IPR estoppel applies only to “grounds” based on patents and printed publications and not to device-based grounds. Citing Ingenico as a “change of law,” defendant moved for reconsideration of the court’s ruling, and the court granted the motion.

...

Read More

IP Newsflash

August 5, 2025

In a recent decision designated as Informative, the USPTO Director determined that the Patent Trial and Appeal Board abused its discretion by instituting two inter partes review proceedings challenging the same patent, based on petitions advancing different constructions of the same claim term. The Director expressed concerns that permitting multiple petitions based on alternative claim constructions effectively circumvents word count limitations, strains board resources, and undermines procedural efficiency.

...

Read More

IP Newsflash

July 25, 2025

Earlier this year, the Federal Circuit’s decision in Qualcomm Inc. v. Apple Inc. (Qualcomm II) raised questions about the extent to which petitioners can rely on applicant admitted prior art (“AAPA”) in inter partes review proceedings.  The Federal Circuit’s recent decision in Shockwave Medical, Inc. v. Cardiovascular Sys., Inc. largely cabins the Qualcomm II decision to its particular facts and makes clear that AAPA can be used as evidence of background knowledge as part of an obviousness argument.

...

Read More

IP Newsflash

July 11, 2025

The Federal Circuit recently reversed a PTAB determination on remand that a patent was obvious over applicant admitted prior art (“AAPA”) in combination with prior art patents, holding that expressly designating AAPA as a “basis” for a ground is improper under 35 U.S.C. § 311(b). In doing so, the Court rejected the PTAB’s “blanket rule” that “AAPA used in combination with prior art patents or printed publications under § 311(b) is ipso facto not the basis or part of the basis of a ground.” Ultimately, while the case clarifies that expressly listing AAPA in an IPR ground is improper, the precise line between proper and improper uses of AAPA in other instances remains unclear.

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.